Inspire Investing LLC Has $391,000 Stock Holdings in Biohaven Ltd. $BHVN

Inspire Investing LLC raised its holdings in Biohaven Ltd. (NYSE:BHVN) by 94.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,692 shares of the company’s stock after purchasing an additional 13,443 shares during the quarter. Inspire Investing LLC’s holdings in Biohaven were worth $391,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. SVB Wealth LLC acquired a new stake in shares of Biohaven in the 1st quarter valued at $25,000. PNC Financial Services Group Inc. grew its position in Biohaven by 53.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company’s stock worth $43,000 after acquiring an additional 623 shares during the last quarter. IFP Advisors Inc grew its position in Biohaven by 84,800.0% during the 1st quarter. IFP Advisors Inc now owns 2,547 shares of the company’s stock worth $61,000 after acquiring an additional 2,544 shares during the last quarter. KBC Group NV grew its position in Biohaven by 35.0% during the 1st quarter. KBC Group NV now owns 4,560 shares of the company’s stock worth $110,000 after acquiring an additional 1,183 shares during the last quarter. Finally, US Bancorp DE grew its position in Biohaven by 62.8% during the 1st quarter. US Bancorp DE now owns 4,837 shares of the company’s stock worth $116,000 after acquiring an additional 1,866 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Bank of America reduced their price objective on Biohaven from $50.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. UBS Group reduced their price objective on Biohaven from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Citigroup assumed coverage on Biohaven in a research report on Wednesday, September 17th. They set a “buy” rating and a $28.00 price objective on the stock. BTIG Research boosted their price objective on Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 19th. Finally, Morgan Stanley cut their target price on Biohaven from $63.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 12th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $48.85.

Biohaven Stock Up 8.1%

Shares of BHVN opened at $16.55 on Wednesday. The company has a market capitalization of $1.75 billion, a PE ratio of -2.16 and a beta of 1.03. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 1.91. The stock’s 50-day moving average price is $15.01 and its two-hundred day moving average price is $16.20. Biohaven Ltd. has a 12 month low of $12.79 and a 12 month high of $54.98.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.94) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.94). On average, analysts anticipate that Biohaven Ltd. will post -8.9 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.